期刊文献+

功能化二氧化锰纳米颗粒的构建及在光动力治疗中的应用 被引量:1

Synthesis of manganese dioxide-based nanocomposites and their application in photodynamic therapy
在线阅读 下载PDF
导出
摘要 肿瘤内部缺氧、偏酸的微环境在一定程度上影响光动力疗法(photodynamic therapy,PDT)的抗癌效果。二氧化锰(MnO_(2))具有优异的氧化性能和催化能力,能响应肿瘤微环境释放氧气,改善PDT疗效。以MnO_(2)纳米片作为骨架材料,共载二氢卟吩e6(Ce6)和三苯基膦修饰的氯尼达明(TPP-LND),获得纳米复合材料MnO_(2)-Ce6@TPP-LND(MCTL)。所得MCTL尺寸相对均匀且具有良好的H_(2)O_(2)和pH双敏感特性。相较于单独的Ce6,MCTL在肿瘤细胞中的富集量更高。经PDT处理后,MCTL的活性氧产率增加,肿瘤细胞的凋亡率加剧,存活率显著下降。研究结果为MCTL进一步实现临床光动力治疗肿瘤提供了实验依据。 The anticancer effect of photodynamic therapy(PDT)in tumors is affected by intratumoral hypoxia and acidic microenvironment.Manganese dioxide(MnO_(2))has excellent oxidation-reduction(REDOX)and catalytic capacities,which can response to tumor microenvironment to release oxygen and improve the therapeutic effect of PDT.In this study,nanocomposites MnO_(2)-Ce6@TPP-LND(MCTL)were obtained by using MnO_(2) nanosheets as the framework material and loading with photosensitizer Ce6 and lonidamine(LND)modified by triphenylphosphine(TPP).The synthesized MCTL showed relatively uniform sizes as well as good H_(2)O_(2) and pH response characteristics.Compared with Ce6 alone,MCTL exhibited higher enrichment in tumor cells.After combining with PDT,the production of reactive oxygen species by MCTL enhanced and the damage of tumor cells aggravated,ultimately leading to the significant decrease of tumor cell survival rate.These results provide experimental basis for the clinical application of MCTL in photodynamic therapy against tumor.
作者 冯晓兰 吴盼盼 吴嘉仪 张坤 FENG Xiaolan;WU Panpan;WU Jiayi;ZHANG Kun(School of Life Sciences,Shaanxi Normal University,Xi'an 710119,Shaanxi,China)
出处 《陕西师范大学学报(自然科学版)》 CAS CSCD 北大核心 2023年第3期43-52,共10页 Journal of Shaanxi Normal University:Natural Science Edition
基金 国家自然科学基金(61905137) 陕西省自然科学基金(2020JQ-411,2020JM-275) 中国博士后项目(2019M653862XB) 中央高校基本科研业务费专项(GK202105004)。
关键词 光动力疗法 二氢卟吩e6(Ce6) 二氧化锰 氯尼达明 乳腺癌 photodynamic therapy chlorin e6(Ce6) manganese dioxide lonidamine breast cancer
作者简介 通信作者:张坤,女,副教授,硕士生导师,研究方向为声光动力抗肿瘤治疗。E-mail:zkxian@snnu.edu.cn。
  • 相关文献

参考文献2

二级参考文献33

  • 1刘娟,冯国龙,贺玉林.抗肿瘤药氯尼达明的研究进展[J].生物技术世界,2013,10(7):74-74. 被引量:1
  • 2牛红蕊,崔艳慧,刘晶,寇小格,路平.国产吉西他滨联合卡铂治疗晚期非小细胞肺癌近期临床观察[J].中国肿瘤临床,2007,34(15):857-859. 被引量:11
  • 3Newell DR, Mansi J, Hardy J, et al. The pharmacokinetics of oral lonidamine in breast and lung cancer patients[J].Semin Oncol, 1991, 18(2 Suppl4): 11-17.
  • 4Passalacqua R, Bisagni G, Bertusi M, et al. Lonidamine in advanced colorectal cancer:a phase Ⅱ study of the Italian Oncology Group for Clinical Research(GOIRC)[J]. Tumori, 1989, 75(3): 277-279.
  • 5Stahl M, SchmoU E, Becker H, et al. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase Ⅱ study[J]. Semin Oncol, 1991, 18(2 Suppl 4):33-37.
  • 6Pronzato P, Amoroso D, BerteUi G, et al. Phase Ⅱ study of lonidamine in metastatic breast cancer[J].Br J Cancer, 1989, 59(2): 251-253.
  • 7束永前,主编.肿瘤科疾病诊断流程与治疗进展[M].北京:科学出版社.2008.2.
  • 8Silvestrini B. Lonidamine:an overview[J].Semin Oncol, 1991, 18(2 Suppl 4): 2-6.
  • 9Robustelli della Cuna G, Pedrazzofi P. Toxicity and clinical tolerance of lonidamine[J]. Semin Oncol, 1991, 18(2 Suppl 4): 18-22.
  • 10Silvestrini B, Hahn GM, Cioli V, ct al. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumolar systems[l]. Br J Cancer, 1983,47(2): 221-231.

共引文献6

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部